About Us

Page 21234..1020..»

The Coronavirus Crisis: ‘Liberal Swine’ How the Kremlin Exploits the Pandemic for Propaganda – Byline Times

Posted: March 31, 2020 at 10:43 pm

Kseniya Kirillova exposes the attempts to discredit the West, undermine Ukraine, and persecute dissidents in the current Russian disinformation campaign.

Coronavirus is gripping the world and cannot, of course, be ignored by Russian propagandists. Recently, several Russian experts explored the basic trends in reporting on the crisis by the Kremlin-controlled mass media in Russia. Based on that commentary and analysis, here are the Russian President Vladimir Putins basic goals in relation to the COVID-19 pandemic.

As predicted not long ago by Aleskander Morozov, a Russian journalist and researcher at the Boris Nemtsov Academic Centre in Prague, the main narrative of the Russian mass media is that the Russian authorities are calmly and effectively combating the virus, while in Europe and the US, governments are fomenting hysteria and instituting incorrect measures that are heavily criticised by the people.

He notes that to the domestic audience, this will be presented as a holistic picture of Moscows superiority and the helplessness of the West.

Declarations that Russia deployed effective preventive measures in time, and that this is why the number of people infected with the Coronavirus is allegedly so low in the country in comparison with the US, have been repeated by leading American broadcasters.

In the face of crisis and panic caused by the Coronavirus, the so-called Western democratic powers displayed total powerlessness and no desire to provide mutual assistance, declared the Russian political commentator Yevgeniy Satanovskiy.At the same time, they are ready to spend energy criticising countries that cope with difficulties an order of magnitude better than themselves, for example, Russia.

Even assuming that Russian officials are not intentionally concealing the number of Coronavirus cases, it is simply impossible to identify all patients in the context of Russian medicine which raises questions not only about the quality of testing, but also the inaccessibility of any quality medical services in the Russian hinterland.

In April 2017, the official Kremlin Vesti site admitted that a substantial closure of hospitals and clinics had occurred in Russia. Those who wish to be treated at home are no better. At the beginning of 2016, the Urals complained of an increase in mortality due to the flu, caused by the lack of imported drugs. Even the pro-Government newspaper Izvestia was forced to admit that pharmacies and hospitals possessed only 65% of the items on the list of essential drugs, with all the medicines listed as vital and most important not to be found anywhere in the Russian Federation.

It is impossible to imagine that, under such conditions, every provincial clinic of those still open could be supplied with quality testing kits for the new Coronavirus.

The Russian inclination to build potemkin villages is also important here. According to Anastasiya Vasilyeva, a representative of the Alliance of Physicians professional union, the authorities are hiding instances of COVID-19 by describing them as pneumonia or serious respiratory infections. According to the Federal State Statistics Service, cases of pneumonia in January 2020 in Moscow increased by 37% compared with the previous year.

It is therefore impossible to prove the number of undetected cases, precisely because they are not detected, which permits Moscow to continue to flaunt low figures.

As part of this propaganda goal, the West is not positioned as weak, helpless and unable to cope with difficulties, but as cold-blooded and calculatingly evil.

Thus, a patriotic blogger, well known for bullying dissidents and spreading Kremlin propaganda far beyond the confines of the Urals, has been very successful in formulating the narrative constantly repeated by the central channels: Poland, like the Czech Republic and USA, appropriated the supply of medical aid to Italy. The European Union is more a nest of snakes enclosed in a glass jar, you die today, Ill die tomorrow.

In this way, the EU and the US are blamed, not only for apparently not helping Italy, but for killing her.

The website Military View, close to the Russian Ministry of Defense, went even further in disseminating a conspiracy theory according to which the pandemic was purposely initiated by the global elites in order to blame it for the collapse of Western Civilisation.

As one author postulates: The Coronovirus has become the Hitler of our time which may be blamed for all the sins and mistakes of the global elite (de facto mafia) Everything crumbles.And these processes obviously are coordinated. The Western elites were prepared in advance, the collapse was agreed. Thus, Coronavirus is an integral part of a big game, the cover operation, the veil behind which the global elites concealed the reboot of the matrix.

At the very beginning of the pandemic, the Russian oppositionrightly feared that alarm over the Coronavirus could be used as a means to continue Putins attack on civil rights, specifically, forbidding protest activities.

When it became obvious that this was a crisis, and European governments closed their borders and imposed quarantines one after another, the Kremlin did not fail to exploit the situation and accuse its critics of applying a double standard to similar actions undertaken by different countries.

Moreover, Russian propaganda used its spinning of the Coronavirus crisis to, at the same time, highlight how the downing of Flight MH17, the Skripal poisoning in the UK, and accusations of interference in the 2016 US Presidential Election were all examples of information warfare against Russia.

Beyond this, under the pretense of combating fake news about Coronavirus, Russia mounted a campaign against all forms of information it decided to call fake, including a Reporters Without Borders report examining the infringement of free speech in Russia. The campaigns founder, Aleksandr Malkevich,demanded the most severe and public punishment for the dissemination of fakes.

This goal involves accusing the opposition of spreading the Coronavirus.

For instance, Oleg Matveechev, Professor of Philosophy at the Higher School of Economics, publicly called for a return to 1937 a reference to Joseph Stalins Great Purge and demanded a massive repression of liberals.

It is this swine who will infect others, he said.It is because of this liberal swine that our loved ones are dying.They are not only dangerous as a Fifth Column in the information war.They are killing us. And therefore, they must be surgically destroyed All participants in rallies and others who subscribe to the opposition.

We should remember that the pretext for the creation of the Warsaw Ghetto in 1940 was the myth that Jews were carriers of infectious diseases.

Unlike the Russians, Ukraine has not concealed the fact that it does not have tests to detect all instances of the Coronavirus and Kiev has therefore instituted a strict quarantine.

Russia is attempting to characterise Ukraine as a danger for all the civilised world and is betting that the EU will not renew its no-visa regime with the country after the quarantine.

Attempts to present the situation in Ukraine as much worse than in Russia are most likely aimed at Crimeans who, according to many observers, have been significantly disappointed in Russia over the past six years.

Nevertheless, Russian propaganda is unlikely to achieve the desired effect, especially given the fact that the epidemiological situation in the country itself is deteriorating every day. People focused on their own health and safety are much less interested in what is happening in other countries, and Russia has never been a country whose priorities included the health of its citizens.

Excerpt from:
The Coronavirus Crisis: 'Liberal Swine' How the Kremlin Exploits the Pandemic for Propaganda - Byline Times

Laughter is the best medicine, says caring doc fighting coronavirus on his elderly care unit – The Sun

Posted: at 10:43 pm

OUR NHS heroes are going the extra mile to keep the nation safe and save lives during the current coronavirus pandemic.

Today we hear from Consultant Physician Dr Bijay Sinha on how he is helping to keep up the spirits of staff and patients on his elderly care unit.

AS the consultant in charge of the elderly care unit in a busy hospital, Dr Bijay Sinha could be forgiven for feeling anxious right now.

All 20 of the patients on my ward have coronavirus. The whole ward is now positive, he explains.

With the over-70s more at risk of falling seriously ill if they contract it, Dr Sinha and his colleagues on Syringa Ward at Whipps Cross Hospital in East London are under immense pressure to care for their vulnerable patients.

Those who do not have the virus have been transferred to other units, but Dr Sinha predicts the remaining six beds will be used for more coronavirus patients.

He says: In a few days we will be full.


Don't miss the latest news and figures - and essential advice for you and your family.

To receive The Sun's Coronavirus newsletter in your inbox every tea time, sign up here.

To follow us on Facebook, simply 'Like' our Coronavirus page.

Get Britain's best-selling newspaper delivered to your smartphone or tablet each day - find out more.

I always have a smile on my face. Happy staff make for happy patients

But the 56-year-old medic a finalist in our Who Cares Wins Health Awards last year is doing his best to keep his patients and staff upbeat.

He says: I make sure I am out on the ward so they can see Im there.

I always have a smile on my face. If Im down or looking low, how will that make the staff and patients feel? They will think, He is worried and so should we be.

Happy staff make for happy patients.

Dr Sinha qualified as a doctor in India in 1992.

He moved to the UK five years later to train here.

He has worked in elderly care for more than a decade and has run Syringa Ward for the past seven years.

He also works at the outpatient clinic The Connaught Day Hospital, on the same site.

As well as caring for his patients, Dr Sinha has had to cope with many of his staff being forced to self-isolate at home because they have symptoms of the virus.

He says: At the moment four of my consultants are off work. They send me messages saying they are getting very bored.

We are a very close-knit unit and support each other.

We have a WhatsApp group and we try to share jokes to boost morale.

Its always good to have a great laugh. It is good medicine.

And he is not the only NHS worker trying to stay upbeat.

Medics at St Thomas Hospital in central London posed for a selfie in their personal protection equipment and nurse Ashleigh Linsdell, from Pilgrim Hospital in Boston, Lincs, has co-ordinated a nationwide group of volunteers to make urgently-needed scrubs for NHS workers.

Dr Sinha runs an Employee Of The Month scheme for his team and before the pandemic he always ensured that birth-days and wedding anniversaries for both patients and staff were celebrated when possible.

He also organised a breakfast club, exercise group and music therapy for his patients, though these are now on hold.

He and other staff members also did a sponsored run, raising nearly 3,000 for equipment for the unit, which is known for its high discharge and low readmission rates.

Dr Sinha says: Im so passionate about what I do and the care I give. I dont believe our job stops when someone goes home.

A holistic approach to care will mean people who go home can stay at home.

Despite working extremely long hours running a busy ward, particularly during this latest crisis, the consultant still manages to keep a positive attitude.

He says: When I come home I just forget about work. Sometimes I feel tired but it is important to keep talking.

Care and share thats the thing.

Dr Sinha says he is lucky because his wife, Rekha, is also a doctor.

She works as a consultant in obstetrics and gynaecology at Basildon University Hospital in Essex.He explains: We both understand the pressures.

The couple have a 16-year-old son, Varul, who Dr Sinha says helps his parents, though he adds: He is studying but says he doesnt want to be a doctor!

Dr Sinhas nomination for a Who Cares Wins award last year was in the Best Doctor category and came from the son of a patient.

Nominate your hero

YOU can help celebrate our nations matchless National Health Service at The Suns fourth annual Who Cares Wins awards.

We will honour the individuals and teams who are bravely facing the current unprecedented health crisis on our behalf.

Nominations for the 2020 awards will open soon.

Sanjay Chandara, 54, got in touch with The Sun to praise the medic for his dignity and dedication while caring for his father, Jayantilal.

Jayantilal was a patient at The Connaught Day Hospital, where he spent three years under Dr Sinhas care.

He suffered from rheumatoid arthritis and multiple health problems relating to the condition.

Speaking at the time of his nomination, Sanjay, from South Woodford, East London, said: My father was a proud man but recurring health issues and several inpatient stays would leave him feeling very low sometimes.

Dr Sinha would always pick up on this and spend extra time with him, despite having an entire ward to look after.

It meant the world to Dad to know someone with such compassion cared for him.

After Jayantilal died in July last year aged 84, Dr Sinha even went to his funeral.

Following his nomination the doctor said: I had met almost every member of his family in those three years and his son said his dad would be very pleased if I could come to the funeral.

It was an honour.

He said he was speechless when he was nominated for one of our awards.

Sex SecretsProstitute who earns 2,000 a week reveals the average penis size ... and how much she enjoys work

PASSION PEAKSThis is the age when your sex drive will be at its most rampant (and girls, it might surprise you)

The boy with no faceTeenager with a huge facial tumour undergoes surgery after it starts to suffocate him

Sexual kneadsWe try trendy new vagina 'massage' but at 250 a session, pleasure comes at a price

CHIN UPThe truth about YOUR double chin, what's really causing it - and the DAFT exercises that can help banish it

Home remediesWhat causes mouth ulcers and how to treat them with stuff you have at home

Dr Sinha added: I treat every patient the same and always try to give them the very best care.

Being nominated gives me the energy to carry on and do the good work. Its the boost you need.

If someone appreciates your work, it makes you feel good.

The rest is here:
Laughter is the best medicine, says caring doc fighting coronavirus on his elderly care unit - The Sun

The Global Hematopoietic Stem Cells Transplantation (Hsct) Market is expected to grow by USD 4.64 bn during 2020-2024, progressing at a CAGR of 6%…

Posted: at 10:43 pm

New York, March 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hematopoietic Stem Cells Transplantation (Hsct) Market 2020-2024" - https://www.reportlinker.com/p05126601/?utm_source=GNW 64 bn during 2020-2024, progressing at a CAGR of 6% during the forecast period. Our reports on global hematopoietic stem cells transplantation (HSCT) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by availability of technologically advanced equipment. In addition, growing demand for personalized medicine is anticipated to boost the growth of the global hematopoietic stem cells transplantation (HSCT) market as well.

Market Segmentation The global hematopoietic stem cells transplantation (HSCT) market is segmented as below: Type: Autologous HSCT Allogeneic HSCT

Geographic Segmentation: Asia Europe North America ROW

Key Trends for global hematopoietic stem cells transplantation (HSCT) market growth This study identifies growing demand for personalized medicine as the prime reasons driving the global hematopoietic stem cells transplantation (HSCT) market growth during the next few years.

Prominent vendors in global hematopoietic stem cells transplantation (HSCT) market We provide a detailed analysis of around 25 vendors operating in the global hematopoietic stem cells transplantation (HSCT) market 2020-2024, including some of the vendors such as AllCells Corp., bluebird bio Inc., FUJIFILM Holdings Corp., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck & Co. Inc., Sanofi, Takeda Pharmaceutical Co. Ltd. and ThermoGenesis Holdings Inc. . The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.Read the full report: https://www.reportlinker.com/p05126601/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Read more here:
The Global Hematopoietic Stem Cells Transplantation (Hsct) Market is expected to grow by USD 4.64 bn during 2020-2024, progressing at a CAGR of 6%...

UNM leads the Pack on innovative substance use disorder research initiatives – UNM Newsroom

Posted: at 10:43 pm

Substance use disorder and addiction are complex public health problems, vividly evidenced by the ongoing opioid epidemic throughout the country. Also, New Mexico has the highest alcohol-related mortality rate and currently races to address this as well as opioid and methamphetamine addiction rates. Few people understand the complexities of these issues better than Dr. Katie Witkiewitz, Regents' Professor in the UNM Department of Psychology.

I love Albuquerque. I came to UNM to study these disorders. CASAA is internationally renowned for research and treatment of addiction says Witkiewitz, who is originally from rural western New York. Im excited about the enthusiasm the University has shown for our passion on these topics.

UNM Regents' professorKatie Witkiewitz

Witkiewitz is the co-lead convener, along with Dr. Brandi Fink an assistant professor in the Department of Psychiatry and Behavioral Sciences, under President Stokes Grand Challenges initiative on Substance Use Disorders. In addition, her colleagues at the Center on Alcoholism, Substance Abuse, and Addictions (CASAA) have secured further NIH funding as a result of partnerships made through the Grand Challenge. All told, these projects bring in over $7.4million for research at UNM.

Interdisciplinary cooperation as well as partnerships between main campus and the UNM Health Sciences Center (HSC) are central to these projects. Witkiewitz emphasizes the importance of the freedom that the Grand Challenge provides to implement innovative pilot projects and is thrilled with the response of 90 researchers and clinicians across UNM who are eager to address the challenge of substance use disorders in New Mexico.

Taking a whole-team collaborative approach to address a complex problem is incredibly challenging and is likely to be highly rewarding by directly impacting patients lives, she says. We look at addiction science from all angles, from brain research to treatment, cells to society, and prevention to policy.

One of the funded projects wouldnt have happened without the collaborative expertise among UNM faculty in Departments of Family and Community Medicine, Psychology, Psychiatry and Behavioral Sciences, and Emergency Medicine. This particular project, Patient-Centered Team-Based Primary Care to Treat Opioid Use Disorder, Depression, and Other Conditions, has far-reaching implications if successful. The project, awarded to Dr. Robert Rhyne at the UNM HSC with Witkiewitz as a co-investigator, will test a groundbreaking model of care management: providing people with depression and an opioid-use disorder with regular direct contact with a nurse over the telephone for a 12-month period.

The team, which is led by Kaiser Permanente Washington Health Research Institute and also includes collaborators at the University of Washington, will look at whether patients who receive nurse care management are more likely to receive medication treatment for their opioid-use disorder, and more likely to have significant reduction in symptoms of depression. This proactive approach may help patients stay engaged with their treatment options when compared to those who do not have this type of personal outreach from a nurse. If successful, this program could be implemented by federally funded, community-based health care providers in underserved areas.

A second grant led by Witkiewitz and Dr. Kevin Vowles at Queens University in Belfast, Integrated Treatment for Veterans with Co-Occurring Chronic Pain and Opioid Use Disorder, directly resulted from the Grand Challenges initiative and includes investigators from UNM HSC as well as the New Mexico Veterans Administration (VA) Health Care System, and the Puget Sound VA Health Care System.

The project brings together experts to test an innovative behavioral treatment for patients with chronic pain and opioid use disorder. When veterans come home from war with trauma and injuries, they are often treated with opioid pain medication, yet mounting evidence has shown opioids are not effective for the long-term management of pain. Indeed, long-term opioid use for pain often leads to addiction.

Veterans are suffering a second injury of developing an opioid-use disorder from medications. We have effective behavioral treatments that can target pain and distress, as well as opioid use disorder, explains Witkiewitz. This trial will be the first of its kind to test an integrated behavioral treatment at multiple sites. As the wife and granddaughter of veterans, I am proud to serve our veterans in implementing and supporting this project.

If successful in reducing opioid use disorder while reducing chronic pain symptoms, the integrated behavioral therapy will roll out nationwide to all VA health care systems.

In addition to these projects, the Substance Use Disorders Grand Challenge initiative have led to other new grants by CASAA investigators. Dr. Kamilla Venner, Assistant Professor in the Psychology Department, and Dr. Aimee Campbell, Associate Professor of Clinical Psychiatric Social Work (in Psychiatry) at Columbia University Irving Medical Center, co-lead the project Culturally Centering Medications for Opioid Use Disorder with American Indian and Alaska Native Communities.

The opioid overdose epidemic has disproportionately impacted Tribal communities and this project will develop a program-level intervention to support four clinical sites primarily serving American Indians and Alaska Natives to initiate or enhance delivery of medication treatment for opioid use disorder.

By working with the collaborative board, comprised of a diverse group of Native experts and stakeholders, the project centers treatment around the culture of the community viewing addiction within a holistic wellbeing framework. Community participation allows innovative solutions to take shape that will be aligned with American Indian Alaska Native perspectives and thus may increase uptake of the first-line treatment of medications for OUD to help decrease the health inequities.

We have a collaborative board to help guide the development of the intervention to include cultural centering of medication treatment and implementation strategies, says Venner. Interacting with and learning from the collaborative board has been meaningful and productive, as well as a real joy of this work; we look forward to our ongoing partnership.

In the state, there remains a continued need for more knowledge on how best to treat alcohol use disorders. Drs. J. Scott Tonigan and Matthew Pearson, investigators in the UNM Psychology Department and CASAA, also recently began their project, Development of a Comprehensive and Dynamic Alcoholics Anonymous (AA) Model: One Day at a Time. They hope to provide insight into activities, interactions, traditions, and other practices in AA programs and how these practices account for alcohol abstinence.

This study adds significant value to the mission of the Grand Challenge initiative by documenting and disseminating information about how to optimize benefit from the most popular community-based approach for reducing alcohol problems in New Mexico and the United States, says Tonigan.

With these research projects ongoing, Witkiewitz is well on her way to helping UNM achieve the Substance Use Disorders Grand Challenges goal to unite prevention, treatment, and policy in order to address the high social costs and human suffering brought on by substance use disorders.

Originally posted here:
UNM leads the Pack on innovative substance use disorder research initiatives - UNM Newsroom

Open Health Network, Mount Sinai Collaborate on Tool for IBD Patient Care to help patients avoid hospital visits, vital during COVID epidemic – PR Web

Posted: at 10:43 pm

Having a digital provider communication tool for use while the team is all working remotely has been critical to our continued ability to provide high quality care to our IBD patients" Dr. Laurie Keefer, Mount Sinai

MOUNTAIN VIEW, Calif. (PRWEB) March 31, 2020

Mount Sinai Hospital in New York and Open Health Network have collaborated on a digital system to coordinate effective care for thousands of high-risk patients living with Inflammatory Bowel Disease (IBD). The solution is designed to improve patient outcomes, including a reduction in patient complications requiring hospitalization, freeing critical care resources that are under enormous strain at Mount Sinai and other hospitals because of the COVID-19 pandemic.

The GRItT-Pro system is a digital replacement for a manual system designed by Mount Sinai to closely coordinate the care teams responsible for treating patients with complex, chronic, and costly to treat conditions including Crohns disease and ulcerative colitis. Built atop Open Health Networks blockchain-based core framework for healthcare, a pilot version of GRItT-Pro was created in just two months with no coding from scratch.

Immediately scalable, the system eliminates the manual systems limit of 200 simultaneous patients out of the 12,000 IBD patients under the hospitals care. While IBD is the first disease area to be handled by the tool, the tool also has the potential to be applied to a range of other chronic conditions that require long-term, coordinated care.

Managing Complex TreatmentTreating patients with IBD requires a long-term holistic treatment plan that involves a diverse set of specialized providers, making it the third costliest disease after heart disease and cancer. In addition, many of those patients also are dealing with stress, anxiety or depression as a result of their disease. That can interfere with their ability to follow their treatment plans or communicate with the care team, and as a result lead to worsened symptoms, diminished outcomes, reduced quality of life, and an increased likelihood of surgery.

As a result, they fall through the cracks, and nobody keeps track of them between appointments, said Laurie Keefer, PhD, a health psychologist at Mount Sinais Susan and Leonard Feinstein Inflammatory Bowel Diseases Clinical Center.

That inspired Mount Sinai to create a proprietary scoring and care team management system called Gaining Resilience through Transitions (GRItTTM). The method allowed for greater coordination of care, but it was paper-based, with time consuming manual entry and challenging communications among the team. Open Healths core framework enabled the team to create a more powerful digital system that automated the information exchange among providers.

An Integrated Solution for Providers and PatientsThe GRItT-PRO tool presents everything about a case to each member of the care team instantly on a provider dashboard. This allows the care coordinator as well as the team to understand the particular situation faced by each patient and respond to that by changing or adding various care routines. A pilot version of the clinician-facing GRITT tool is currently undergoing initial clinical testing, and a fully integrated patient-facing component is being created.

Our platform was created specifically to address the needs of healthcare, including the crucial issues of privacy and cost-effective development, said Tatyana Kanzaveli, CEO of Open Health. Our team was able to collaborate with Mount Sinai and understand exactly what they needed and produce it very quickly with existing modules.

Reducing Hospital and In-Person Visits to Free ResourcesThe tool also integrates with Mount Sinais existing Telehealth services. This ability is important for high-risk IBD patients, who are often reluctant to leave their homes because of the unpredictable nature of their symptoms. It also is vital for providers during times when either a patient or a provider is unable to come to the hospital, as is the case during a public health emergency such as the COVID-19 pandemic.

Having a digital provider communication tool for use while the team is all working remotely has been critical to our continued ability to provide high quality care to our IBD patients, Keefer said.

Case study is available to download at Open Health Network web site.

About Open Health NetworkOpen Health Network is using Blockchain and smart contracts to enable consumers to control and monetize their health information. Powered by Artificial Intelligence and Big Data analytics, our platform enables rapid development of mobile health applications and chatbots for patients, healthcare providers, payers and medical researchers. Learn more at https://www.openhealth.cc.

About the Mount Sinai Health SystemThe Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Read this article:
Open Health Network, Mount Sinai Collaborate on Tool for IBD Patient Care to help patients avoid hospital visits, vital during COVID epidemic - PR Web

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations – Yahoo Finance

Posted: at 10:42 pm




PLANO, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of severe, life-threatening diseases, today provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations. The Company announced measures it is taking to protect the health and safety of patients and health care workers involved in ongoing clinical studies of its investigational medicines, as well as its employees and collaborators.

Clinical Programs

Reata conducts clinical studies in many countries around the world that are being impacted by the COVID-19 pandemic. Regulatory agencies, governments, and health care providers have implemented restrictive measures designed to reduce potential exposure to the virus, particularly for patients at increased risk of severe illness. For each clinical development program, Reata is working with health care providers to implement changes that mitigate risk to patients; comply with regulatory, institutional, and government guidance; and maintain the integrity of our ongoing clinical studies.

Drug Supply Chain

Reatas current inventory of investigational product is adequate to support its ongoing clinical trials. Based on current evaluations, the Company believes that its supply chains are adequate to meet its 2020 clinical, nonclinical, and chemistry, manufacturing and control supply demands across all programs. The Company is alert to the potential for disruptions that could arise from COVID-19 and remains in close contact with suppliers.

Business Operations

In accordance with recommendations from local, state, and national health authorities, Reata has implemented work-from-home measures and additional safety protocols to protect employees and the broader community and to ensure business continuity. The Company has restricted on-site staff to only those required to execute their job responsibilities and limited the number of staff working in its research and development laboratory. The Company has suspended all in-person meetings and international travel, and it has sharply limited travel within the United States. Reata has also suspended attendance at medical congresses, conferences, and other large events. The Company continues to monitor this dynamic situation closely, and it will take additional measures as required to preserve the safety of its employees and broader community.

The COVID-19 pandemic presents an unprecedented threat to public health, said Warren Huff, Reatas Chief Executive Officer and President. The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment. We will continue to monitor and make adjustments, if needed, as we navigate this highly fluid landscape.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reatas two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Forward-Looking Statements

This press release includes certain disclosures that contain forward-looking statements, including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as believes, will, may, aims, plans, model, and expects. Forward-looking statements are based on Reatas current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reatas filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, under the caption Risk Factors. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Story continues

See the original post:
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations - Yahoo Finance

GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic – GlobeNewswire

Posted: at 10:42 pm

GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic

Lille (France), Cambridge (Massachusetts, United States), March 31, 2020 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today reported an update on its regulatory and clinical activities in the context of the COVID-19 pandemic.

The unprecedented spread of COVID-19 is impacting the global health and business ecosystem, GENFIT included. During this crisis, our priorities are to ensure the safety and well-being of our employees, of the patients and healthcare professionals involved in our clinical trials, as well as the integrity of our ongoing clinical trials.

GENFIT is therefore monitoring the situation closely and, in light of our priorities and in accordance with the recently issued guidance documents of the U.S. Food and Drug Administration (FDA) and European Medicines Agency, we have worked with our contract research organizations, trial sites and investigators to critically reassess all our existing programs.

RESOLVE-IT Phase 3 trial in NASH with fibrosis continues

As announced previously, the first ~1000 patients required to support regulatory approval have completed their final visits and the database related to that cohort was locked at the end of February, as planned. The un-blinding of the study and subsequent announcement of interim results will take place after receipt and incorporation of insight from the FDA. We do not currently anticipate that the COVID-19 situation will significantly delay receipt of this feedback.

After careful consideration of the potential benefits to NASH patients in continuing treatment, we have also decided to continue the extension phase of RESOLVE-IT. Working with our contract research organization, we have implemented appropriate measures to ensure the safety of patients who are already participating in the study: virtual clinic visits, local laboratory assessment, home delivery of study drug, and halting the screening of new patients. Additional measures may be implemented, as required by the evolving COVID-19 situation.

Other trials are paused

Following guidance from regulatory authority recommendations and prioritizing the safety of our clinical trial participants, all phase 1 trials which include pharmacokinetic, food effect and bioequivalence studies have been put on hold. These studies are necessary to support the elafibranor NDA submission for NASH.

Enrollment of patients in the PK/PD trial in pediatric patients with NASH as well as the Phase 2 study addressing liver fat have also been paused.

While our NASH combination and PBC programs both continue with several work streams still being executed, we have decided to put on hold the initiation of the Phase 2 combination study, as well as that of the Phase 3 study in patients with PBC.

All supporting activities pertaining to continuation of ongoing studies or the initiation of new studies will continue in order to minimize potential delays when the pandemic crisis subsides.

NIS4 Diagnostic

Our diagnostic solution continues to be deployed in the clinical research field through our commercial partner Covance, a subsidiary of diagnostics leader LabCorp. While interest in NIS4 is high, there may be some limits in test utilization due to delays potentially experienced by some NIS4 clients as the result of the current COVID-19 situation.

GENFIT teams are progressing the in-vitro diagnostic (IVD) aspect of the program in parallel.

Supply chain update

Although the COVID-19 pandemic is rapidly evolving, and our plans may change accordingly, at this stage we do not anticipate any supply disruption for any of our current or planned studies. We have on hand sufficient supply of elafibranor for all our clinical studies up to mid-2021, and we do not foresee any issues with supply of raw materials and production of commercial batches. Likewise, our partners and the GENFIT teams have put in place contingency plans to manage the operational aspects of our ongoing and planned trials, even under the current conditions.

Employee update

Our employees are fully committed and are doing their best to ensure business continuity during this crisis. The measures we have deployed are fully aligned with governmental measures recommended for impacted countries and will be adjusted as the situation evolves. These measures enable GENFIT to pursue the vast majority of our activities, while abiding by health authorities sanitary recommendations: remote work has been enacted for all compatible positions, social distancing measures are applied for employees still working in the office, safety protection procedures are enforced, and business travel is strictly limited to that which is considered absolutely critical for the Companys operations.


RESOLVE-IT is a phase 3 study evaluating the efficacy and safety of elafibranor 120mg versus placebo in patients with nonalcoholic steatohepatitis (NASH) and fibrosis. It is a multicenter, randomized, double-blind, placebo-controlled study with 2 arms. It is conducted under Subpart H (FDA) and conditional approval (EMA). Treatment duration until interim analysis for accelerated approval is 72 weeks.

ABOUT ELAFIBRANORElafibranor, GENFITs lead pipeline therapeutic candidate, has been developed to treat, in particular, nonalcoholic steatohepatitis (NASH), for which it has been granted Fast Track Designation by FDA. Elafibranor is an oral, once-daily, first-in-class drug acting via dual agonism of peroxisome proliferator-activated alpha/delta receptors. Elafibranor was granted a Breakthrough Therapy Designation by FDA in this indication.


NASH is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with an increased risk of cardiovascular disease along with long-term risk for progression to cirrhosis, leading to liver insufficiency and potential progression to liver cancer. NASH is a serious disease that often carries no symptoms in its early stages, but if left untreated can result in cirrhosis, cancer, and the need for liver transplant. The prevalence of NASH is rapidly increasing as a result of the growing obesity and diabetes epidemics and is believed to affect as much as 12 percent of people in the U.S. and six percent worldwide.


Primary biliary cholangitis (PBC) is a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed. The damage to bile ducts can inhibit the livers ability to rid the body of toxins, and can lead to scarring of liver tissue, known as cirrhosis.


GENFIT is developing NIS4, a blood-based diagnostic test to identify patients with NASH and fibrosis (F>2, NAS>4), who are the focus of current NASH clinical trials. The NIS4 program is based on the in-house discovery of a 4-biomarker algorithm, and GENFIT is currently pursuing commercialization of this test, which aims to be a validated alternative to the liver biopsy. In January 2019, GENFIT signed a licensing agreement with LabCorp to make the NIS4 diagnostic kit available in the clinical research field, and GENFIT plans to file an application with the FDA for approval of NIS4 as an in vitro diagnostic (IVD) .


GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (RESOLVE-IT) as a potential treatment for NASH, and GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in PBC. As part of GENFITs comprehensive approach to clinical management of patients with NASH, the company is also developing a new, non-invasive blood-based diagnostic test, NIS4, which, if approved, could enable easier identification of patients with NASH. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and in compartment B of Euronexts regulated market in Paris (Nasdaq and Euronext: GNFT). http://www.genfit.com


This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including timing of anticipated receipt of FDA insights regarding elafibranor in NASH and incorporation of such insight, appropriateness of safety measures in the continuing RESOLVE-IT Phase 3 clinical trial, ability to continue supporting activities and to minimize potential delays once the COVID-19 pandemic subsides, potential for supply disruptions for our ongoing and planned clinical studies and impact of the COVID-19 pandemic on our operations and timelines. The use of certain words, including believe, potential, expect and will, provisional and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Companys management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates and the Companys continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Companys public filings with the French Autorit des marchs financiers (AMF), including those listed in Section 4 Main Risks and Uncertainties of the Companys 2018 Registration Document filed with the AMF on February 27, 2019 under n D.19-0078, which is available on GENFITs website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC), including the Companys final prospectus dated March 26, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. In addition, even if the Companys results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.


GENFIT | Investors

Naomi EICHENBAUM Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com


Hlne LAVIN Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com

GENFIT | 885 Avenue Eugne Avine, 59120 Loos - FRANCE | +333 2016 4000 | http://www.genfit.com

Continued here:
GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic - GlobeNewswire

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the…

Posted: at 10:42 pm

OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus.

The company is targeting the United States, Europe, Asia and Argentina for its clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development. AIM intends, as a next step, to as rapidly as possible seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials of Ampligen as both a protective prophylaxis and an early-onset therapy.

AIM has reached several significant COVID-19 milestones over the past two months:

"Since the first news of the outbreak, our focus and efforts have been devoted to developing Ampligen as an intranasal and oral protective prophylaxis and as an intravenous early-onset treatment for this highly pathogenic coronavirus. As front-line workers fighting the pandemic around the world know - and as their families know - they are putting their lives on the line every day by working with COVID-19 patients. For example, health care workers account for a reported 13% of cases in Spain. I have a son and a nephew who are doctors, a daughter and a sister who are nurses, three nephews who are EMTs, and one nephew who is a police officer. This fight is personal to me, as it is to countless others around the globe. In the absence of an effective vaccine, the development of early-stage therapies such as Ampligen may be critical both to the health of our front-line workers and to blunt the spread of the pandemic," said AIM CEO Thomas K. Equels.

AIM also continues to await results in the six ongoing clinical trials studying the effects of Ampligen on different types of cancers, where steady progress continues to be made. The company will update stockholders and the market as more information on these studies becomes available. To that point, today the company filed a duly executed amendment to its Material Transfer and Research Agreement with Roswell Park Comprehensive Cancer Center, attaching an exhibit showing the clinical trials currently underway or on deck. Cancer patients are especially at risk with COVID-19. We also recognize that all cancer centers, like all medical facilities, must make the pandemic their priority. Therefore, there is the potential for delays in clinical trial enrollment and reporting in ongoing studies in cancer patients as a consequence of the COVID-19 medical emergency.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen or Rintamod) and the FDA-approved drug Alferon N Injection. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. Some of the world's largest pharmaceutical companies are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first priority or that, even if Ampligen proves effective, another treatment that eventually proves effective will not make our efforts ultimately unproductive. No assurance can be given that future studies will not result in findings that are different from those reported in studies we are relying on. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks. With regard to the Company's activities with Ampligen generally, no assurance can be given as to whether current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference herein and is included for reference purposes only.

Story continues

See the original post:
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the...

COVID-19 keeps local family from seeing their loved one who is an Alzheimer’s patient – WATN – Local 24

Posted: at 10:41 pm

MEMPHIS, Tennessee

As a result of the COVID-19 outbreak, places such as nursing homes and assisted living facilities have been on lock down. This means outside visitors, including family members, are not allowed inside. Last month, Local 24 News introduced the public to a husband whose wife is an Alzheimer's patient at a memory care facility. He spoke again. This time, he talked about how the virus outbreak has impacted his family.

It hasn't bloomed, but the flowers in Judy's room are Easter lilies.

"That's one of Judy's favorite plants that I give her every year for Easter," said Warner Gregory, Judy's husband.

It is a tradition showing love even when one may not remember. Judy has Alzheimer's disease. Up until recently, as a result of the coronavirus, Warner was able to visit her each week.

"I call Diversicare where she is and I said, 'Well, at least can I come get her clothes and wash them?' Nope, nobody in and nobody out," said Gregory. "The bulk of the people where Judy is are prime for this disease to hit them. That's why I can't go see her."

It has been three weeks since Warner has last seen Judy and he has one main fear.

"That's hard on our hearts if she should pass while she's in there. We're not going to be able to tell her goodbye and that will be tough," said Gregory. "I want to see her."

Local 24 News asked Gregory what he would tell Judy if he could see her.

"I love her. That's all that counts," said Gregory.

Until then, the plant rooted in love, stemmed from a gesture will now bloom in new memories.

"The Easter lily I give to my wife, I'm going to give to my daughter for Easter. Pass that onto her," said Gregory. "I'll tell Casie. This is what you're mom usually gets, but I'll give it to you this year."

Warner said he keeps calm by staying busy. He checks in frequently with Judy's nurses who tell him she is doing well.

View original post here:
COVID-19 keeps local family from seeing their loved one who is an Alzheimer's patient - WATN - Local 24

Does Aspirin Reduce the Risk of Alzheimer’s Disease? – MedicalResearch.com

Posted: at 10:41 pm

MedicalResearch.com Interview with:

Joanne Ryan,PhDSenior Research Fellow,ASPREEFrom the School of Public Health and Preventive MedicineMonash UniversityMelbourne, Australia

MedicalResearch.com: What is the background for this study?

Response: Aspirin is a commonly used drug knownto reduce inflammation, and prevent blood clotting (antiplatelet) which is why it is commonly used in secondary prevention in individuals with establishedcardiovascular disease.

Inflammation is thought to be a central mechanismin Alzheimers disease, implicated in the neuropathological cascade leading to the development of dementia and other forms of dementia.

Cardiovascular risk factors and stroke are both associated with cognitive decline and an increased risk of dementia.

This formed the basis of the hypothesis that aspirin could be beneficial in helping to reduce cognitive decline and the occurrence of Alzheimers Disease.

MedicalResearch.com: What are the main findings?

Response: Unfortunately, the main findings of our study do not support this hypothesis.

Instead the results showed that among 19,114 older individuals over 5 years, those randomised to aspirin compared to placebo, did not have a reduced risk of developing Alzehimers disease.

Furthermore, aspirin and placebo groups did not show any differences in terms of milder losses of memory or thinking ability.

MedicalResearch.com: What should readers take away from your report?

Response: This paper indicates that aspirin should not be prescribedsolely on the basis of potential cognitive benefits as there is no evidence to suggest this, nor that low-dose aspirin could reduce the risk of Alzheimers disease.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: The cognitive health of ASPREE participants is being tracked in the follow-up ASPREE-XT study to determine whether the benefits of aspirin may become apparent later on.Because dementia can take years to develop, it is possible that ASPREE was not a long enough trial to show possible benefits from aspirin, so we will continue to examine for long-lasting effects of aspirin in study participants in the coming years. The ASPREE participants were aged 65 years and older at the start of the trial. The findings therefore do not address the question of whether low-dose aspirin initiated at a younger age could be beneficial.

I have nothing to disclose.


Joanne Ryan, Elsdon Storey, Anne M. Murray, Robyn L. Woods, Rory Wolfe, Christopher M. Reid, Mark R. Nelson, Trevor T.J. Chong, Jeff D. Williamson, Stephanie A. Ward, Jessica E. Lockery, Suzanne G. Orchard, Ruth Trevaks, Brenda Kirpach, Anne B. Newman, Michael E. Ernst, John J. McNeil, Raj C. Shah.Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.Neurology, 2020; 10.1212/WNL.0000000000009277 DOI:10.1212/WNL.0000000000009277

We respect your privacy and will never share your details.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Continued here:
Does Aspirin Reduce the Risk of Alzheimer's Disease? - MedicalResearch.com

The New Study finds a New Biomarker in Blood for Early Detection of Alzheimer’s disease – TheHealthMania

Posted: at 10:41 pm

A new study published in the journal Current Biology by the researchers at the University of California San Diego discovers that high blood levels of RNA delivered by the PHGDH gene could fill in as a biomarker for early recognition of Alzheimers disease. The work could prompt the advancement of a blood test to distinguish people who will build up the disease years before the side effects shown by them.

The proteins and RNA that are produced by the PHGDH gene are basic for mental health and functions in newborn children, kids and teenagers. As individuals get older, the gene ordinarily inclines down its creation of these proteins and RNAs.

Study in detail here.

The lead author of the study is a professor of bioengineering at the UC San Diego Jacobs School of Engineering in collaboration, Sheng Zhong proposes that the PHGDH gene causes the overproduction of a kind of RNA, called extracellular RNA (exRNA) that could give an early admonition indication of Alzheimers ailment in older people.

Read more-New Research Shows Air Pollution Is One of the Top Causes of Death Worldwide

Sheng Zhong tells that A few realized changes related with Alzheimers ailment for the most part appear around the hour of clinical finding, which is excessively late. Researchers suspected that there is an molecular predictor that would show up a long time previously, and that is the thing that persuaded this investigation

This discovery is just made due to a technique created by Zhong and colleagues that is sufficiently enough to succession countless exRNAs in under one drop of blood. The strategy, named SILVER-SEQ, was utilized to examine the exRNA profiles in blood tests of more than thirty old people 70 years and those who were checked as long as 15 years before death.

The outcomes indicated a precarious increment in PHGDH exRNA creation in all converters roughly two years before they were clinically determined to have Alzheimers. PHGDH exRNA levels were on normal higher in Alzheimers patients. An expanding pattern wasnt shown in the controls, aside from in one control that got named a converter.

Zhong further tells that the scientists noted some vulnerability in regards to the irregular converter. Since the subject died at some point during the 15-year checking, it is indistinct whether that individual would have undoubtedly built up Alzheimers if the person lived longer.

The co-first author, Zixu Zhou who is a bioengineering alumnus from Zhongs lab, explains that this is a review study dependent on clinical subsequent meet-ups from the past, not a randomized clinical preliminary on a bigger sample size. So researchers are not yet calling this a checked blood test for Alzheimers disease.

In this study, the data from clinically gathered samples strongly bolster the revelation of a biomarker for anticipating the development of Alzheimers disease. In addition to randomized preliminaries, future examinations will incorporate testing if the PHGDH biomarker can be utilized to recognize patients who will react to drugs for Alzheimers ailment.

Read more-The New Study Finds that Psychiatric disorders Cause Pregnancy Issues

The team is also open to collaborating with Alzheimers research groups that might be interested in testing and validating this biomarker.

The studys team is also working together with Alzheimers research group that may be keen on testing and approving this biomarker.

Koo tells that if the outcomes of this study can be recreated by different centres and extended to more cases, at that point it recommends that there are biomarkers outside of the brain that are modified before clinical disease onset and that these progressions additionally foresee the conceivable onset or development of Alzheimers malady.

If this PDGDH signal is demonstrated to be precise, it tends to be very educational for diagnosis and treatment response for Alzheimers examination.

View original post here:
The New Study finds a New Biomarker in Blood for Early Detection of Alzheimer's disease - TheHealthMania

Strongsville nursing facility sends caregivers home with essentials as thanks for taking care of residents – WJW FOX 8 News Cleveland

Posted: at 10:41 pm

Please enable Javascript to watch this video

STRONGSVILLE, Ohio (WJW) -- In light of the coronavirus outbreak, a Strongsville nursing facility is taking some extra special care of the employees who care for its residents every single day.

The staff at Kemper House cares for those with all stages and types of Alzheimer's disease, dementia and end of life and hospice care.

"With the recent outbreak of the Coronavirus virus, the staff works tirelessly round the clock to provide comfort, love, and security to the most vulnerable of people, our elderly Alzheimers residents," said a press release from the facility. "They are also working diligently to prevent an outbreak of the Covid19 virus. Nursing homes and assisted livings are emerging as the front lines in the fight against the Coronavirus."

The management team at Kemper House packed grocery bags full of paper towels, toilet paper, Clorox wipes, hand sanitizer and other essentials along with a large bag of oranges for the staff to take home to their families.

They handed out the bags Friday, so the employees would have enough over the weekend.

Our top priority is the safety and well-being of our residents and of our staff," said Kristin West, Operations Director for Kemper House. We are a team and we are in this together.

Check out the pictures below for more.

How are you seeing Clevelands Own helping Clevelands Own in your community?Tell us by clicking here.

Read the original:
Strongsville nursing facility sends caregivers home with essentials as thanks for taking care of residents - WJW FOX 8 News Cleveland

Alzheimer’s Disease Drug Market is expected to expand at the highest CAGR by 2028 : Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma – Bandera…

Posted: at 10:41 pm

Alzheimers Disease Drug Market Overview Forecast To 2028

The research report contains a detailed summary of the Global Alzheimers Disease Drug Market that includes various well-known organizations, manufacturers, vendors, key market players who are leading in terms of revenue generation, sales, dynamic market changes, end-user demands, products and services offered, restricted elements in the market, products and other processes. Technical advancements, market bifurcation, surplus capacity in the developing Alzheimers Disease Drug markets, globalization, regulations, production and packaging are some of the factors covered in this report.

The research report on Global Alzheimers Disease Drug Market is a detailed study of the current market scenario, covering the key market trends and dynamics. The report also presents a logical evaluation of the major challenges faced by the leading market players operating in the market, which helps the participants to understand the barriers and challenges they may face in future while functioning in the international market over the forecast 2020-2028.

The following manufacturersare assessed in this report in terms of sales, revenue, and market share for each company:Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck

Geta PDF SampleCopy (including TOC, Tables, and Figures) @https://garnerinsights.com/2013-2028-Report-on-Global-Alzheimers-Disease-Drug-Market-by-Player-Region-Type-Application-and-Sales-Channel#request-sample

Types of Alzheimers Disease Drug covered are: DonepezilMemantineRivastigmine

Applications of Alzheimers Disease Drug covered are: Early to Moderate StagesModerate to Severe Stages

The Global Alzheimers Disease Drug Market report analyses the production of goods, supply, sales, and the current status of the market in a detailed manner. Furthermore, the report examines the production shares and market product sales, as well as the capacity, production capacity, trends in sales, cost analysis, and revenue generation. Several other factors such as import/export status, industrial statistics, demand and supply ratio, gross margin, and industry chain structure have also been studied in the Global Alzheimers Disease Drug Market report.

To get this report at a profitable rate, Click Herehttps://garnerinsights.com/2013-2028-Report-on-Global-Alzheimers-Disease-Drug-Market-by-Player-Region-Type-Application-and-Sales-Channel#discount

Regional Analysis For Alzheimers Disease DrugMarket

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Get Full Report Description, TOC, Table of Figures, Chart, etc. @https://garnerinsights.com/2013-2028-Report-on-Global-Alzheimers-Disease-Drug-Market-by-Player-Region-Type-Application-and-Sales-Channel

Table of Contents:

Study Coverage:It includes key manufacturers covered, key market segments, the scope of products offered in the global Alzheimers Disease Drugmarket, years considered, and study objectives. Additionally, it touches the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary:It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region:Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers:Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

The objectives of the report are:

To analyze and forecast the market size of Alzheimers Disease DrugIndustry in theglobal market. To study the global key players, SWOT analysis, value and global market share for leading players. To determine, explain and forecast the market by type, end use, and region. To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions. To find out significant trends and factors driving or restraining the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To critically analyze each submarket in terms of individual growth trend and their contribution to the market. To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market. To strategically outline the key players and comprehensively analyze their growth strategies.

Get Full Report @ https://garnerinsights.com/2013-2028-Report-on-Global-Alzheimers-Disease-Drug-Market-by-Player-Region-Type-Application-and-Sales-Channel

The growth of this market globally is subjected to various factors, including consumer ace Alzheimers Disease Drugof a lot of Alzheimers Disease Drugproducts, inorganic company growth models, price volatility of raw materials, product innovation along with economic prospects in both producer and consumer countries.

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: sales@garnerinsights.com

View post:
Alzheimer's Disease Drug Market is expected to expand at the highest CAGR by 2028 : Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma - Bandera...

Altru Family YMCA offers online fitness options to enhance health at home – Grand Forks Herald

Posted: March 30, 2020 at 7:49 pm

Thanks to virtual technology and social media, there are many resources available that are easily accessible from home or office, said Patti McEnroe, YMCA membership and marketing director.

She recommended three free options that are available to everyone who has wifi, McEnroe said.

Developed by the YMCA of the USA, the YTRAAK Stay Healthy-Y 600 Challenge encourages friendly competition between U.S. states. The winning states will be decided by a point system that is calculated and displayed in real time in the participants profile and on the stats page, McEnroe said.

The team with the most points at the end of the challenge will be the winner of the match. In North Dakota, the competition, which started March 23, has drawn more than 6,000 participants who track time spent in activities, such as biking, running, walking and Y360 classes, she said.

Fitness categories include strength training, cardio and mind-body -- the latter involves activities, such as meditation and yoga. Go to http://www.ytraak.org.

A group of YMCAs have collaborated to create an on-demand healthy living network, YMCA 360, which includes virtual programs, in a class platform, that can be accessed anywhere.

It offers all kinds of different classes that people can do anytime," McEnroe said.

The content is accessible on the YMCA 360 YouTube Channel, http://www.YMCA360.org.

Ive put my yoga flex class on YouTube, she added.

Silver Sneakers and Silver and Fit members can access online classes and other programming that offers a vast array of workouts that are relatively short, McEnroe said. The workouts are very similar to the classes we offer at the Y.

Theres also a phone number participants can call if they have any difficulties accessing the programs, said McEnroe, adding that both organizations are very accommodating.

For more information, visit http://www.silversneakers.com or http://www.silverandfit.com .

During this unsettled time, we are continually exploring alternative ways to meet the needs of our Greater Grand Forks community and beyond, McEnroe said. People should take advantage of these options. Its so important to help people keep healthy and feeling more positive and upbeat. We just have to keep people moving.

View original post here:
Altru Family YMCA offers online fitness options to enhance health at home - Grand Forks Herald

UREC Shifts Fitness Workouts and Recreational Challenges to Online to Keep You Hale and Hearty – University of Arkansas Newswire

Posted: at 7:49 pm

Just as faculty and students are adjusting to doing coursework online, University Recreation is making the shift to online programming. A few options include group fitness classes, at-home workouts, outdoor recreation opportunities, intramural sports, and various health and wellness tips and challenges.

"We know that with our facilities being closed, participants are having to get creative with their workout routines, and we want to do what we can to help them," said Casey Fant, assistant director of fitness and wellness.

University Recreation is bringing back its Commit to Fit challenge to encourage the campus community to stay committed to their own well-being while working remotely from home. Participants will earn points by logging their physical activity each week during the month of April. Prizes will be awarded to those who complete 600 minutes during the month of April. This challenge is free. Registration opens on Monday, March 30 at fitevent.uark.edu.

A variety of UREC group fitness classes will be available via Zoom to the entire U of A community. This will launch on Monday, March 30. Participants can find the schedule and log-in details here on the UREC website. Live classes are scheduled throughout the day on Monday, Wednesday, and Friday during the week of March 30. An updated schedule will be provided each week.

"During this time, we see an immediate need to deliver a fitness experience into the homes of our participants," said Fant.

For at-home workouts, follow our social media channels @urecarkansas or visit theUREC YouTube channelto access online exercise videos led by certified group fitness instructors.

University Recreation is encouraging people to get outdoors to exercise during this time while keeping in mind the recommended CDC guidelines for safe social distancing.

"I like the idea of keeping some sense of normalcy and engagement as a university community. This is something familiar, which is much appreciated during this uncertain time," said Mike Hoover, associate director of assessment, staff development, and outdoors.

"A simple walk outside can do a world of good for mental health," said Hoover. "People can use this as an opportunity to exercise in a different way."

Additionally, UREC Sports will be hosting a variety of virtual events.Events include a 5K, e-sports, and trivia contests.

More online programming will become available in the coming weeks. Please visit http://www.urec.uark.edufor details on all of our programming options.

Follow this link:
UREC Shifts Fitness Workouts and Recreational Challenges to Online to Keep You Hale and Hearty - University of Arkansas Newswire

Timberwolves helping players maintain their mental and emotional fitness, too – Minneapolis Star Tribune

Posted: at 7:49 pm

A box showed up at Malik Beasleys door Thursday, sent from Timberwolves President Gersson Rosas and Vice President of Performance and Technology Robby Sikka.

The contents, however, werent meant for Beasley. Instead, they were for Beasleys son, Makai, who was celebrating his first birthday. Inside were Spider-Man toys, a coloring book with some crayons and of course some sports gear. Beasley posted his thanks on Instagram to Rosas and Sikka, who got a big assist assembling the box from Rachel Saunders, the manager of team services.

This is emblematic of the approach the Wolves have tried to take with players as they deal with the coronavirus pandemic to try to be there for their players and their families as they navigate this crisis.

Its one that has already hit home in a major way for the organization, with center Karl-Anthony Towns revealing his that mother, Jacqueline Cruz, was recently admitted to a hospital and was put in a medically induced coma as she battles COVID-19, the illness this novel strain of coronavirus causes. Towns father, Karl Sr., also reportedly tested positive and is recovering.

All their families are a part of our family, and if they hurt, we hurt, Rosas said. With Karl and all our guys, its been a checking in, making sure that theyre doing well, not just physically but mentally, emotionally as best as we can.

The physical challenge the Wolves have addressed. They have sent players exercise equipment, given them workout routines they can do from home and helped players find living quarters that include basketball courts where they can at least take a ball and shoot. That has been important because Rosas estimated 70-80% of the team is still in Minnesota.

But just as important, if not more so, than the physical aspect is making sure players are healthy from a mental standpoint. Its something that hasnt been easy since the NBA suspended its season March 11.

These are young people that are in the throes of a really traumatic time, said Sikka, who told the team this will be their generations 9/11, a landmark event they will remember where they were when it began. Everybody has to absorb information in the ways that they are built. Everybody has different things that motivate them, that cause fear, and we cant communicate with each player the same. Weve got to make sure that we tailor what we do to the individual and give them the sense that theyre the priority.

To do that, the Wolves have been leaning on the expertise of Sikka; Gregg Farnam, the teams longtime head athletic trainer; and Justin Anderson, the team psychologist. Anderson has been doing video check-ins with players to help them cope with the psychological aspect of not playing a sport they love and of the concerns they might have being alone or concerns about their family.

When people get pulled out of the thing that makes them them, they have some shifts in their identity, Anderson said. Who am I? Without this sport, who am I? And a lot of these guys havent had to answer that because theyve been in this sport 24/7. So it can really impact you from a psychological perspective.

Anderson said he has told players he sees the pandemic playing out in four stages from a psychological standpoint.

The first has passed the uncertainty around the season and what the government response to the virus would be. The second is what everyone is going through now, the isolation phase.

Guys are really bored, Anderson said. And that boredom, combined with isolation, its a new thing for folks.

The third phase is going to be anger, fear and depression. Its a phase when the virus hits home or impacts families and friends, like what Towns is going through.

Stage 4 is coming out on the other side and seeing what changes come from going through this situation.

Anderson has said life without basketball can be difficult for players, especially when it was yanked so suddenly from their lives.

A lot of these guys, sport has been the thing that has kept them sane, Anderson said. Its been their sanctuary. And when you take that away from them, it really can impact them. When youre around a team and getting better and competing, theres just a lot of socialization and a lot of stuff that goes back and forth from that. These tend to be the outlet.

Added Rosas, I think all of us feel it.

Rosas said the Wolves have been forming de facto book clubs and podcast clubs filled with literature and content on leadership and motivational talks to help keep players engaged. Anderson said one book they have recommended is The Inner Game of Tennis by W. Timothy Gallwey, a book that talks about competition within the mind and is a seminal work in the field of sports psychology.

Rosas said the front office is still preparing for the June draft and going over scenarios related to the likely drop in next seasons salary cap from the lost revenue of postponing the season.

Sikka said the Wolves have had some unsung heroes in this crisis, such as head equipment manager Peter Warden and assistant GM Joe Branch, who have been making sure players have every need addressed.

The business of basketball still goes on for the Wolves, even in this uncharted form.

This problem and the things that it has raised across this country are going to linger for years and years to come, Sikka said. It will change the way we consume sports. It will change the way we live, change the way we treat each other.

The Wolves are trying to make sure that last part doesnt change much from what they already were doing.

Read more:
Timberwolves helping players maintain their mental and emotional fitness, too - Minneapolis Star Tribune

25 Deals on Outdoor and Fitness Gear You Won’t Want to Miss – Gear Patrol

Posted: at 7:49 pm

Yeti Hopper Backflip

Save 20%: Backcountry is offering shoppers 20 percent off one full-price item with the code 20FULLPRICE, which means you can finally get Yetis most portable cooler at a discount.

Save 15%: Stock up the snack drawer. Use code DISCOUNT-STOCK-THE-PANTRY-15 at checkout.

Save 25%: Hiking season hasnt been canceled yet, and Vasques best boots are 25 percent off.

Save 25%: The North Face upgraded its workhorse rain jacket with its innovative new fabric material, FutureLight.

Save 25%: A trail running shoe so iconic, people have started wearing it on sidewalks, too.

Save 45%: Road runners arent the only ones who can revel in Adidass cushy Boost foam.

Save 25%: One of this Swedish gear makers most beloved products is this pair of rugged hiking pants.

Save 15%: Taken up a socially distant sport like running or cycling? Heres your fuel. Use code DISCOUNT-STOCK-THE-PANTRY-15 at checkout.

Save 15%: One of the most versatile headlamps available also comes with one of the most approachable prices.

Save 33%: A lined training short made by the maker of some of the most comfortable underwear available. You connect the dots.

Save 26%: Working out at home? Count a proper mat made with eight-millimeter high-density foam among your fitness essentials.

Save 25%: Kuju Coffees highly portable pour-over kits are ideal for camping, but theyre perfect for a quick home cup, too.

Save 22%: This packable polyester puffer features Comfortemp high thermal synthetic fill to keep you cozy as well as stylish.

Save 25%: A removable hood, underarm vents and the Omni-Tech waterproof/breathable treatment ensure optimal climate control when the skies open.

Save 25%: The triple-layered, vacuum-insulated construction of this good-looking vessel keeps beverages cold for up to 24 hours or hot for up to 12.

Save 25%: This ultralight setup weighs less than 7 pounds while accommodating up to four campers comfortably.

Save 20%: In honor of its sixth anniversary, Cotopaxi is offering 20 percent off sitewide with promo code ANNIVERSARY20. Were making a beeline for the $44 in savings on this bombproof pack.

Save up to 40%: One of our all-time favorite insulated jackets is 30 to 40 percent off in a range of colors and sizes.

Save 25%: Theraguns flagship percussion massager will bump-bump-bump your workout recovery to the next level.

Save up to 46%: These innovative running shoes provide a cushy sensation perfect for recovery days.

Save 46%: Perfect for cool-weather workouts, this hoodie is water-repellent, sweat-wicking and built with abrasion-resistant panels.

Save 51%: This streamlined runner is perfect for daily road work and perfectly serviceable for gym routines too.

Save 25%: Weighing in at just 9.2 ounces, this jacket will keep you warm and dry whether your hiking takes place on mountains or from block to block.

Save 25%: This quarter-zip top boasts natural stretch, insulation and breathability, making it ideal for layering or as a standalone piece on warmer days.

Save 10%: This hardtails lightweight carbon frame and 29-inch wheels make it a total blast on cross-country trails.

See the rest here:
25 Deals on Outdoor and Fitness Gear You Won't Want to Miss - Gear Patrol

With most closed due to COVID-19 pandemic, fitness studios bring the workouts home – WGN-TV

Posted: at 7:49 pm

Posted: Mar 29, 2020 / 01:02 PM CDT / Updated: Mar 29, 2020 / 01:02 PM CDT

Please enable Javascript to watch this video

CHICAGO - Everyday life in most ways has been interrupted during the last two weeks because of the COVID-19 pandemic.

With a shelter-in-place order in effect in Illinois, most gatherings over ten people have been canceled for the foreseeable future. For gyms and fitness studios, this means no activities whatsoever until the pandemic is more under control.

That's forced many trainers and coaches to bring their classes online as they try to help people stay in shape while staying indoors.

Josh Frydman caught up with those who run The Barre Code in Lakeview and MV Fitness Chicago to see how they're reaching out to clients over the next few weeks. You can watch the story in the video above.

See the original post here:
With most closed due to COVID-19 pandemic, fitness studios bring the workouts home - WGN-TV

The evolutionary dynamics and fitness landscape of clonal hematopoiesis – Science Magazine

Posted: at 7:49 pm

Evolutionary dynamics in hematopoiesis

Cells accumulate mutations as we age, and these mutations can be a source of diseases such as cancer. How cells containing mutations evolve, are maintained, and proliferate within the body has not been well characterized. Using a quantitative framework, Watson et al. applied population genetic theory to estimate mutation accumulation in cells in blood from sequencing data derived from nearly 50,000 healthy individuals (see the Perspective by Curtis). By evaluating how mutations differ between blood cell populations, a phenomenon known as clonal hematopoiesis, the researchers could observe how recurrent mutations can drive certain clonal lineages to high frequencies within an individual. The risk of specific mutations, some of which are associated with leukemias, rising to high frequencies may therefore be a function of cellular selection and the age at which the mutation originated.

Science, this issue p. 1449; see also p. 1426

Somatic mutations acquired in healthy tissues as we age are major determinants of cancer risk. Whether variants confer a fitness advantage or rise to detectable frequencies by chance remains largely unknown. Blood sequencing data from ~50,000 individuals reveal how mutation, genetic drift, and fitness shape the genetic diversity of healthy blood (clonal hematopoiesis). We show that positive selection, not drift, is the major force shaping clonal hematopoiesis, provide bounds on the number of hematopoietic stem cells, and quantify the fitness advantages of key pathogenic variants, at single-nucleotide resolution, as well as the distribution of fitness effects (fitness landscape) within commonly mutated driver genes. These data are consistent with clonal hematopoiesis being driven by a continuing risk of mutations and clonal expansions that become increasingly detectable with age.

Continue reading here:
The evolutionary dynamics and fitness landscape of clonal hematopoiesis - Science Magazine

Boston Fitness Studios find deeper connection with community online – Daily Free Press

Posted: at 7:49 pm

Fitness classes have routinely united Bostonians in exercise, experience and the thrill of completing a common goal. But with the COVID-19 pandemic, Boston fitness studios are embracing new opportunities to connect with their members despite the distance.

Following Gov. Charlie Bakers order that all non-essential businesses halt in-person operations until April 7, the fitness business has been exploring creative ways of remote teaching, in which people can practice pilates, yoga and even cardio at home.

Sweat Fixx

Elise Caira, the owner and instructor of Sweat Fixx, a fitness studio specializing in full body rowing and sculpting workouts in Massachusetts, said they launched live streams of classes the day after they closed. While customers cannot visit their locations one of which is in South Boston she said online classes have united the community in a time where sticking with the routine is crucial.

People love to be able to still connect with our instructors in the community, and through our live-streaming, theyre able to see everybody work hard [and] sweat together, Caira said. I feel like its made our community even tighter than it was before.

While there was a learning curve for people to learn how to sign up and access the classes, Caira said the community has been very responsive. She said the company also launched Sweat Fixx Stream 360, where a variety of pre-recorded classes can be streamed anytime.

Were finding this little niche that we never knew about that works well, Caira said. People from all other states have been connecting with us now and taking our classes. So [online classes are] something that were definitely going to explore in the future.

Despite the challenges of the coronavirus, Caira said she thinks this experience has made her team stronger.

Weve had a lot of good luck with our studios and I feel like this is good because it humbles you, and it makes you appreciate what you have, Caira said. It brings your team together closer so that they can be resilient and work through the hurdles.

Down Under School of Yoga

Down Under School of Yoga is offering over 20 live-streamed classes a day at a variety of times throughout the day and evening, with one location near campus in Brookline.

Sami Lea Konczewski, the director of marketing, brand and strategic planning and instructor at Down Under, said the flexibility of online classes allows more people to join than normal classroom sizes allow, including participants from countries around the world.

The first day that we had live streaming, we had over 900 people come to the classes, Konczewski said. Weve seen an influx of not only local students but people from all over the world. Weve had people from Brazil and Japan and Canada and India, from all over.

Although the pandemic has created a challenge for Down Under as a small business, Konczewski said it has allowed her to realize the strength of their community and to evolve.

We definitely are feeling the financial anxiety, Konczewski said, but weve also been able to realize that our community is really strong and really supportive.

Konczewski said she has seen yoga become a haven for people in this difficult time.

Weve been able to see the need for yoga at a time like this, Konczewski said. We have been able to be a support system and a conduit for the removal of fear for people.

Upward Spiral Studio

Cambridge-based Upward Spiral Studio is offering between four and seven group classes online each day, as well as private classes through Zoom in pilates, Gyrokinesis and conditioning, according to the website.

Paula Spina, one of three co-owners of the studio, said that it is important to offer those because exercise can allow people to take care of themselves.

The clients of ours have an opportunity now to continue taking care of themselves by working out and taking time for themselves, Spina said. Theyre getting their self care, theyre getting their exercise, theyre getting their socialization, theyre getting their sense of community.

Martha Mason, another co-owner at Upward Spiral, said the studio hopes to add classes that will help people cope with the crisis.

Were thinking of offering some classes that would give people coping skills, or how to access your inner creativity, Mason said. Well either make those free or inexpensive because more than ever, everybody needs something for their mind and spirit, and we want to honor that.

Upward Spiral hopes to continue online classes after the pandemic, Spina said, because of the positive responses they have received. She said she has loved online classes because of the opportunity to meet peoples pets and husbands and connect in a deeper way.

Its a new kind of intimacy, if you will, Spina said. You have to let barriers down in a weird way to let it happen. And then when everyones doing it, its bringing us more sense of community.

Read the original post:
Boston Fitness Studios find deeper connection with community online - Daily Free Press

« Previous Post  Next Posts »

Page 21234..1020..»